First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
3D CMOS chip for connecting electroactive tissues and organoids to software
The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Subscribe To Our Newsletter & Stay Updated
